Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-03-04 Sale | 2024-03-05 4:10 pm | Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel | 2,297 | $32.99 | $75,778 | 128,323 (Direct) | View |
| 2024-03-04 Sale | 2024-03-05 4:10 pm | Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer | 605 | $32.99 | $19,959 | 116,542 (Direct) | View |
| 2024-01-08 Sale | 2024-01-10 4:15 pm | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 2,275 | $28.87 | $65,682 | 43,927 (Direct) | View |
| 2024-01-03 Sale | 2024-01-05 4:51 pm | Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO | 19,223 | $29.46 | $566,310 | 904,901 (Indirect Direct) | View |
| 2024-01-03 Sale | 2024-01-05 4:50 pm | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 5,843 | $29.46 | $172,135 | 54,372 (Direct) | View |
| 2024-01-03 Sale | 2024-01-05 4:50 pm | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 5,532 | $29.46 | $162,973 | 46,202 (Direct) | View |
| 2024-01-03 Sale | 2024-01-05 4:49 pm | Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer | 5,365 | $29.46 | $158,053 | 40,585 (Direct) | View |
| 2024-01-03 Sale | 2024-01-05 4:46 pm | Intellia Therapeutics Inc. | NTLA | Hicks Derek EVP, Chief Business Officer | 3,877 | $29.46 | $114,216 | 36,987 (Direct) | View |
| 2024-01-03 Sale | 2024-01-05 4:45 pm | Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel | 3,805 | $29.46 | $112,095 | 51,474 (Direct) | View |
| 2024-01-03 Sale | 2024-01-05 4:44 pm | Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer | 4,608 | $29.5 | $135,954 | 40,845 (Direct) | View |
| 2023-10-31 Sale | 2023-11-02 4:42 pm | Intellia Therapeutics Inc. | NTLA | Bhanji Muna Director | 265 | $23.9 | $6,334 | 11,996 (Direct) | View |
| 2023-07-31 Sale | 2023-08-02 5:19 pm | Intellia Therapeutics Inc. | NTLA | Bhanji Muna Director | 265 | $42.33 | $11,217 | 12,261 (Direct) | View |
| 2023-07-06 Sale | 2023-07-10 5:21 pm | Intellia Therapeutics Inc. | NTLA | Bhanji Muna Director | 1,867 | $39.3 | $73,373 | 12,526 (Direct) | View |
| 2023-07-03 Sale | 2023-07-06 3:34 pm | Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer | 360 | $40.51 | $14,584 | 45,146 (Direct) | View |
| 2023-06-20 Sale | 2023-06-22 5:52 pm | Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer | 5,000 | $45 | $225,000 | 102,896 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
Ownership | 2024-04-22 4:10 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | Dube Michael P Principal Accounting Officer | 0 | $0 | 31,223 (Direct) | View |
| 2024-03-01 Option Award | 2024-03-05 4:10 pm | N/A 2034-02-28 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 92,760 | $0 | 136,687 (Direct) | View |
| 2024-03-01 Option Award | 2024-03-05 4:10 pm | N/A 2034-02-28 | Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel | 79,146 | $0 | 128,323 (Direct) | View |
| 2024-03-01 Option Award | 2024-03-05 4:10 pm | N/A 2034-02-28 | Intellia Therapeutics Inc. | NTLA | Hicks Derek EVP, Chief Business Officer | 71,814 | $0 | 108,801 (Direct) | View |
| 2024-03-01 Option Award | 2024-03-05 4:10 pm | N/A 2034-02-28 | Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer | 76,302 | $0 | 116,542 (Direct) | View |
| 2024-03-01 Option Award | 2024-03-05 4:10 pm | N/A 2034-02-28 | Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO | 277,515 | $0 | 1,182,416 (Direct) | View |
| 2024-03-01 Option Award | 2024-03-05 4:10 pm | N/A 2034-02-28 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 94,556 | $0 | 148,928 (Direct) | View |
| 2024-03-01 Option Award | 2024-03-05 4:10 pm | N/A 2034-02-28 | Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer | 69,944 | $0 | 110,529 (Direct) | View |
| 2024-01-01 Exercise | 2024-01-03 5:35 pm | 2024-01-01 2031-03-02 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 3,500 | $0 | 55,234 (Direct) | View |
| 2024-01-01 Exercise | 2024-01-03 5:34 pm | 2024-01-01 2031-03-02 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 3,187 | $0 | 63,404 (Direct) | View |
| 2024-01-01 Exercise | 2024-01-03 5:30 pm | 2024-01-01 2031-03-02 | Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO | 7,848 | $0 | 931,974 (Direct) | View |
| 2024-01-01 Exercise | 2024-01-03 5:28 pm | 2024-01-01 2031-03-02 | Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer | 3,062 | $0 | 49,014 (Direct) | View |
| 2023-06-20 Exercise | 2023-06-22 5:52 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer | 5,000 | $12.27 | 102,896 (Direct) | View |
| 2023-06-20 Exercise | 2023-06-22 5:52 pm | N/A 2030-02-02 | Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer | 5,000 | $0 | 102,896 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 4:30 pm | N/A 2033-06-13 | Intellia Therapeutics Inc. | NTLA | CHASE WILLIAM J Director | 4,120 | $0 | 21,403 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 4:29 pm | N/A 2033-06-13 | Intellia Therapeutics Inc. | NTLA | Verwiel Frank Director | 10,898 | $0 | 18,189 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 4:28 pm | N/A 2033-06-13 | Intellia Therapeutics Inc. | NTLA | Keresty Georgia Director | 10,898 | $0 | 22,619 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 4:28 pm | N/A 2033-06-13 | Intellia Therapeutics Inc. | NTLA | GOODMAN JESSE Director | 10,898 | $0 | 18,189 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 4:26 pm | N/A 2033-06-13 | Intellia Therapeutics Inc. | NTLA | Crowley John F Director | 10,898 | $0 | 18,189 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 4:26 pm | N/A 2033-06-13 | Intellia Therapeutics Inc. | NTLA | Cohen Fred E Director | 10,898 | $0 | 48,189 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 4:24 pm | N/A 2033-06-13 | Intellia Therapeutics Inc. | NTLA | Bhanji Muna Director | 10,898 | $0 | 20,866 (Direct) | View |
| 2023-04-14 Option Award | 2023-04-18 5:04 pm | N/A 2033-04-13 | Intellia Therapeutics Inc. | NTLA | CHASE WILLIAM J Director | 25,414 | $0 | 32,214 (Direct) | View |
Ownership | 2023-04-18 4:49 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | CHASE WILLIAM J Director | 0 | $0 | 6,800 (Direct) | View |
| 2023-03-01 Option Award | 2023-03-03 5:31 pm | N/A 2033-02-28 | Intellia Therapeutics Inc. | NTLA | Hicks Derek EVP, Chief Business Officer | 56,845 | $0 | 74,151 (Direct) | View |
| 2023-03-01 Option Award | 2023-03-03 5:20 pm | N/A 2033-02-28 | Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer | 66,318 | $0 | 81,722 (Direct) | View |
| 2023-03-01 Option Award | 2023-03-03 5:18 pm | N/A 2033-02-28 | Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO | 219,667 | $0 | 1,044,907 (Direct) | View |
| 2023-03-01 Option Award | 2023-03-03 5:15 pm | N/A 2033-02-28 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 74,016 | $0 | 99,703 (Direct) | View |
| 2023-03-01 Option Award | 2023-03-03 5:14 pm | N/A 2033-02-28 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 72,240 | $0 | 89,869 (Direct) | View |
| 2023-03-01 Option Award | 2023-03-03 5:12 pm | N/A 2033-02-28 | Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer | 65,347 | $0 | 79,820 (Direct) | View |